Source-grounded facts extracted from ACADIA PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ACADIA PHARMACEUTICALS INC reported the first quarter ended March 31, 2026 results: revenue total revenues of $268 million. Guidance reaffirmed.
“Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm”
Elizabeth H.Z. Thompson retired as Head of Research and Development at ACADIA PHARMACEUTICALS INC.
“On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.”
Brendan Teehan departed as Executive Vice President, Chief Operating Officer and Head of Commercial at ACADIA PHARMACEUTICALS INC.
“On November 18, 2024, Acadia Pharmaceuticals Inc. (the “Company”) agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company’s Management Severance Benefit Plan (the “Severance Plan”)) from his position, effective immediately.”
Catherine Owen Adams was appointed as Chief Executive Officer at ACADIA PHARMACEUTICALS INC.
“On September 20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the “principal executive officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date.”
Stephen R. Davis was terminated as President and Chief Executive Officer at ACADIA PHARMACEUTICALS INC.
“Stephen R. Davis is departing the Company and will be succeeded by Catherine Owen Adams.”
Earnings Releases
ACADIA PHARMACEUTICALS INC reported financial results for the three months ended March 31, 2024.
“On May 8, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2024.”
Earnings Releases
ACADIA PHARMACEUTICALS INC updated its Full Year 2024 guidance (initiated).
“Full Year 2024 Financial Guidance • DAYBUE net product sales in the range of $370 to $420 million. • NUPLAZID net product sales in the range of $560 to $590 million. • GAAP R&D expense in the range of $305 to $325 million. • GAAP SG&A expense in the range of $455 to $480 million.”
Earnings Releases
ACADIA PHARMACEUTICALS INC reported fourth quarter and full year ended December 31, 2023 results: revenue $231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023, net income net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023, EPS $0.28 per common share for the fourth quarter and $(0.37) per common share for the full year.
“Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.